Mateusz Brzeziński

LIVEMarkets rolling coverageStarted: May 10, 2026, 12:00 AM EDTUpdated: May 10, 2026, 11:59 PM EDT ASX 200 Falls Sharply as CSL Shares Plunge May 10, 2026, 11:59 PM EDT. The ASX 200 index dropped sharply following a significant decline in CSL shares, Australia's leading biotech firm. CSL's stock price sank after the company issued a profit warning, rattling investor confidence. The wider market felt the impact due to CSL's substantial weighting in the index. Other sectors experienced mixed reactions as investors reassessed risk amid concerns about earnings outlooks. CSL's profit warning was the catalyst, dragging down the benchmark index and

LIVEMarkets rolling coverageStarted: May 8, 2026, 12:00 AM EDTUpdated: May 8, 2026, 11:59 PM EDT Valuing Commonwealth Bank of Australia Shares Using Dividend Yield and PE Ratio May 8, 2026, 11:19 PM EDT. The Commonwealth Bank of Australia (CBA) shares trade at a PE ratio of 31.2x, considerably above the banking sector average of 19x, indicating potential overvaluation by this metric. Analysts use PE ratio comparisons to assess if shares are priced fairly against peers, but this can be misleading as lower ratios might reflect underlying issues. A more reliable valuation method for CBA involves the Dividend Discount Model (DDM),

LIVEMarkets rolling coverageStarted: May 4, 2026, 12:00 AM EDTUpdated: May 4, 2026, 11:59 PM EDT ASX All Ordinaries Focuses on Governance as AI Oversight Grows May 4, 2026, 11:59 PM EDT. The ASX All Ordinaries index is increasingly highlighting corporate governance amid expanding scrutiny of artificial intelligence (AI) oversight. Investors are paying closer attention to how companies manage risks related to AI technologies, reflecting broader concerns over transparency and accountability. With AI integration accelerating across industries, governance frameworks are adapting to mitigate ethical and operational challenges. This shift aligns with global trends emphasizing responsible AI deployment, aiming to protect stakeholders

LIVEMarkets rolling coverageStarted: April 27, 2026, 12:00 AM EDTUpdated: April 27, 2026, 11:58 PM EDT EVE Health Names Ben Rohr as CEO to Drive Commercial Growth April 27, 2026, 11:58 PM EDT. EVE Health Group (ASX: EVE) has appointed Ben Rohr as CEO, effective immediately, signaling a shift to accelerate commercialisation. Rohr, previously COO, has led key initiatives including the $3 million Nextract acquisition and product integration. He will focus on expanding EVE's reformulated pharmaceutical compounds, specializing in enhanced delivery systems for drugs nearing patent expiry. Current CEO Damian Wood transitions to head regulatory and medical affairs, overseeing clinical development.